HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)
Approximates insulin resistance.
Enter fasting insulin and glucose levels to assess for the likelihood of insulin resistance.
Advice
- There is no universally accepted single cutoff:
- Values between 2.0 and 3.0 are commonly used in U.S. clinical and research settings.
- A cutoff of ≥2.5 is used in NHANES (National Health and Nutrition Examination Survey) to indicate insulin resistance.
- Consider the population and context of use:
- A study of U.S. adults without diabetes (NHANES III) found a HOMA-IR median of 2.2, mean of 2.8, and a standard deviation of 2.4.
- A study of U.S. adolescents found a mean HOMA-IR of 2.3 in normal-weight individuals and 4.9 in individuals with obesity (>50% of whom had insulin resistance).
- Internationally, cutoffs for metabolic syndrome and dysglycemia are lower in Asian populations, typically ranging from 1.4 to 2.5.
Management
- There are no validated management algorithms or guidelines that use this score; however, lifestyle modification is the foundation for reversing early-onset insulin resistance.
- High-intensity interval training (HIIT) or concurrent resistance training combined with a Mediterranean or plant-based diet yields the greatest improvement in HOMA-IR, with practical implementation involving 2–3 sessions per week and a diet rich in fiber, whole grains, fruits, vegetables, and unsaturated fats.
- If lifestyle modifications are insufficient, pharmacological therapy targeting weight loss and cardiovascular comorbidities should be employed.
- Weight loss of 5%–10% can substantially improve insulin sensitivity; for this reason, glucagon-like peptide-1 (GLP-1) receptor agonists or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists, such as tirzepatide, can be prescribed.
- Metformin can also play a role, but it is generally less effective than GLP-1 receptor agonists or dual agonists.